Our Company

Our Platform

Our drug discovery platform s fueled by an exceptional data trove, augmented with artificial intelligence/machine learning, and grounded by stem cell biology.

OUR STORY

Founded in 2021 at Stanford Research Park, Greenstone Biosciences was born from the NAMs revolution. Co-founder Dr. Joseph C. Wu—a two-decade pioneer in iPSC and organoid technologies—partnered with leading computational biologists to launch a platform company predicated on:

Human-First Data

NAMs assays that mirror patient physiology.

AI-Driven Insights

Continuous model learning from real-world and in-house datasets.

Translational Rigor

Direct path from bench to IND, partnering with regulators early.

Our integrated platform underpins two spin-outs:

Cibus Therapeutics

(Palo Alto) – Advancing small-molecule treatments for chronic pancreatitis and IBD using Greenstone-sourced discovery chemistry.

Aerys Biosciences

(Palo Alto) – Developing novel pipelines for idiopathic pulmonary fibrosis and pulmonary arterial hypertension, validated on our NAMs-AI engine.

OUR APPROACH

Discovery & Design

I predicts targets, designs libraries enriched for drug-like properties.

NAMs Validation

High-content hiPSC and organoid assays confirm on-target activity and early safety.

Preclinical Acceleration

Integrated DMPK, toxicology and CMC studies built around NAMs data packages.

Regulatory Engagement

Collaborative data submissions that showcase human-relevant proof points.

TECHNOLOGY

Engineering Tomorrow’s Medicines with NAMs, AI & hiPSCs

Built on 20 years of New Alternative Methods (NAMs) innovation from Stanford, Greenstone Biosciences fuses:

NAM-Enabled hiPSC Platforms

Dr. Joseph C. Wu’s lab advances human-relevant cell and organoid models, accelerating translational readouts and reducing animal use.

AI-Powered Discovery

Proprietary machine-learning pipelines mine multi-omic and phenotypic data to predict efficacy, safety and optimize lead candidates.

High-Throughput Screening

Integrated robotics and imaging workflows deliver rapid NAMs-driven assays across disease-relevant cell types.

This seamless engine moves novel small molecules from target ID to IND-ready assets up to 3× faster, aligned with evolving FDA and global NAMs guidance.

iPSC BIOBANK

Your Gateway to Human-Relevant Models

Leverage our curated library of >2,000 hiPSC lines—healthy controls and patient-derived from diverse genetic backgrounds:

Disease Modeling

Cardiovascular, neurological, hepatic, pulmonary and immunological indications.

Mechanistic Insights

Single-cell profiling and 3D organoid systems reveal novel targets.

Preclinical De-risking

Early NAMs assays predict toxicity and on-target engagement.

Academic investigators may access selected lines free of charge. Transform your research with Gold-standard, regulatory-ready hiPSC models.

COLLABORATORS & PARTNERS

Greenstone Biosciences accelerates drug discovery through human-relevant NAMs and advanced AI technologies. By combining scientific expertise with innovative platforms, we deliver safer, more effective therapies to patients in less time.

hiPSC-Derived Cells

Organoids